RESI Europe Speaker Spotlight: Hear From Family Offices, Big Pharma, And Top VCs

28 Feb

By Lucy Parkinson, VP of Investor Research, LSN

RESI Europe’s two tracks of investor panel content will feature panel discussions that aim to inform entrepreneurs on how raising capital works in their vertical, and how major investor categories such as Family Offices, Angels, Seed Funds, and Big Pharma source and assess new healthcare technologies. With dozens of speakers coming from top firms, LSN would like to introduce you to some of the luminaries who will be appearing at RESI to provide their advice and expertise to attending entrepreneurs.

Chuck Steston, Stetson Family Office, Family Offices & Angels

Eugene W. Stetson started the Stetson Family Office shortly after he personally led the buyout of The Coca-Cola Company through a public offering in August 1919 by the Guaranty Trust Company of New York, where he subsequently served as Chairman and just before he died and organized, he organize with the much smaller J.P. Morgan. At his death, Eugene was Coca-Cola’s longest serving member of the Board and of the Executive Committee. Chuck Stetson, the third generation running the family office, is an entrepreneur, venture capitalist, and philanthropist. The Stetson Family Office started Healthcare Impact Foundation, a 501-c-3 organization, in 2017 to bring capital and management expertise to local life science companies and to build and maintain an efficient life science eco-system composed of R&D facilities, incubation facilities, venture capital investors, angel investors, family office investors, and networks of experts in science, management, industry, reimbursement and public policy. Stetson Family Office has set up a unique Global Family Office BioForum with family offices around the globe working closely with their local healthcare innovation. Family Offices are responding with excitement.

Florence dal Degan, Novo Nordisk, Big Pharma

Florence Dal Degan joined Novo Nordisk A/S in May 2016 as R&D Innovation Sourcing Director. The R&D Innovation Sourcing team of Novo Nordisk is global, with a presence at the Danish Headquarters, as well as a regional presence in Shanghai, Boston, New-York and Paris. Florence is based in Paris and is responsible for search and evaluation of new opportunities within Europe and Middle-East across the therapeutic areas that Novo Nordisk is dedicated to, such as diabetes, obesity, NASH, chronic cardiovascular diseases, nephropathy and haemophilia. Florence has a PhD in biochemistry from The National Institute of Agronomy (Agro-Paris Tech, France). She has over 20 years of experience in Research and Development in academic, biotech and pharma environments. Since 2000, Florence has worked with drug discovery and early development and has held several positions as group leader within R&D. She has been working with external innovation since 2012.

Philipp Rittershaus, High-Tech Gründerfonds, Seed Funds

Dr Philipp Rittershaus studied technical biology in Stuttgart and also obtained an MBA in engineering management alongside his doctorate at B.R.A.I.N. AG. Prior to becoming an Investment Manager at HTGF in 2015, he was a self-employed consultant and implemented a range of life science and spin-off projects. At the HTGF Philipp nurses a portfolio of 10 Life Science Companies.

Marco Boorsma, Forbion, Early Stage Therapeutics

Marco is Partner at Forbion Capital Partners and joined the firm in 2007. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion Marco was Business Development Director and project manager at DSM Pharmaceutical Products and scientist at Cytos Biotechnology in Switzerland. He serves on the Board of Directors of Inflazome, NorthSea Therapeutics, Milestone Pharmaceuticals, Escalier Biosciences, RSPR Pharma, and Engene. After obtaining a master’s degree in molecular biology from the University of Groningen, Marco received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Roel Bulthuis, INKEF Capital, Early Stage Therapeutics

Roel Bulthuis is a Managing Director and head of the Healthcare investment team at INKEF Capital. Roel combines close to 20 years of experience across venture capital, pharma business development and M&A and healthcare investment banking. Prior to joining INKEF he served as SVP and Managing Director of M-Ventures which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global business development and M&A at Merck Serono and in the healthcare investment banking team at Fortis Bank. Roel is a Kauffman Fellow and passionate about continuously challenging the status quo. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: